Trevi Therapeutics (TRVI) Non-Current Debt (2020 - 2022)

Trevi Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $2.2 million for Q4 2022.

• On a quarterly basis, Non-Current Debt fell 75.14% year-over-year to $2.2 million in Q4 2022; TTM through Dec 2022 was $2.2 million, a 75.14% decrease from a year earlier, with the FY2022 full-year figure at $2.2 million, down 75.14% from the prior year.
• Non-Current Debt slipped to $2.2 million in Q4 2022 per TRVI's latest filing, from $3.8 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $14.0 million in Q4 2020 and bottomed at $2.2 million in Q4 2022.
• The 3-year median for Non-Current Debt is $9.4 million (2021), against an average of $9.1 million.
• Across the five-year window, Non-Current Debt fell 25.75% in 2021 and plunged 75.14% in 2022, its largest moves.
• Year by year, Non-Current Debt stood at $14.0 million in 2020, then sank by 38.0% to $8.7 million in 2021, then plunged by 75.14% to $2.2 million in 2022.
• Per Business Quant, the three latest TRVI Non-Current Debt figures stand at $2.2 million (Q4 2022), $3.8 million (Q3 2022), and $5.4 million (Q2 2022).